Join our webinar to discover how our hiPSC-cardiomyocyte platform can accelerate your drug discovery by enabling comprehensive evaluation - from QT interval to contractility, and from acute to chronic - for both cardiac toxicity and therapeutic efficacy!

The heart is a vital organ essential for human life. Given its critical role, a human-relevant model of the heart is indispensable in drug discovery—both for evaluating therapeutic efficacy against cardiac diseases and assessing the risk of cardiac toxicity. However, traditional animal models and conventional ion-channel assays often fail to fully replicate human cardiac physiology, limiting their predictive power in drug discovery. To overcome these challenges, FUJIFILM offers innovative assays using hiPSC-derived cardiomyocytes, which closely recapitulate key phenotypes of human heart cells.

Our platform features a non-invasive multielectrode array (MEA) system that captures electrophysiological properties, enabling high-throughput assessment of QT prolongation and proarrhythmia risks optimized for drug screening phases. This technology also allows detection of chronic drug effects, accelerating safer and more efficient drug development.

In this webinar, we will introduce innovative approaches to extract deeper insights from assays, including detailed evaluation of compound effects on cardiomyocyte electrophysiology such as specific ion-channel inhibition, beat rate, conduction velocity, and contractility.

Key Topics Include:

• Understanding how hiPSC-derived cardiomyocytes replicate human cardiac physiology and their value as tools for drug discovery


• Development of a high-throughput assay for QT prolongation and proarrhythmia risk assessment


• Detection of chronic effects of drug compounds on cardiomyocyte electrophysiology


• Advanced analyses to extract detailed electrophysiological information from hiPSC-derived cardiomyocytes, including identification of specific ion-channel inhibition, beat rate, and conduction velocity


• Approaches to contractility assays leveraging cardiomyocyte maturation technologies